For the three months ended June 30, 2024, from continuing operations: Revenues of $662.4 millionGAAP net loss of$(99.3) millionAdjusted EBITDA of $55.2 millionGAAP and adjusted diluted loss per share of$(1.11) and $(0.03), respectivelyBook-to-bill ratio of 0.96x, resulting in 1.16x book-to-bill for the trailing 12 monthsCompleted divestiture of assets relating to the Endpoint Clinical and Patient Access businessesDebt paydown of$504 million in the quarter using initial divestiture and securitization proc ...